Interleukin-6 (IL-6) has an important role in the pathogenesis of chronic viral hepatitis and related liver diseases. Although host genetics associated with the response to anti-viral treatment have been reported, little is known about the relationship between IL6 genetic polymorphisms and the outcome of hepatitis B virus (HBV) infection. In this study, we determined the genotype distribution of rs1800796 polymorphism in healthy controls and cases including chronic HBV (CHB), hepatitis C virus and HIV infection. The rs1800796 was found to be associated with clinical outcome of CHB in experimental and validation cohort. The rs1800796C allele has twofold higher promoter activity than G allele. Consistently, CD14 + monocytes from subjects carrying the rs1800796C allele produced more IL-6 in response to in vitro HBV core antigen stimulation than those carrying G allele. Moreover, CHB patients carrying rs1800796C allele have significantly higher T-helper 17 (Th17) and regulatory T cell (Treg) ratio. Finally, a transcription factor C/EBPα binds in higher affinity to rs1800796C allele than to G allele. These results suggest that genetic predisposition to higher IL-6 production is associated with increased risk to HBV infection and hepatic inflammation, which might be due to C/EBPα-mediated regulatory effect on Th17 and Treg responses. Appropriate manipulation of IL-6 expression might be used to prevent and treat HBV infection.
INTRODUCTION
Highly prevalent hepatitis B virus (HBV) infection is a major public health challenge in China, where chronic infection is prevalent to perinatal period as well as early childhood (1-3 years). [1] [2] [3] Although chronic HBV (CHB) infection will develop chronic hepatitis, which can progress to cirrhosis and hepatocellular carcinoma (HCC), the natural history of HBV infection varies significantly with individuals and with age of infection. 3 Outcome of HBV infection is influenced by a complex combination of viral, environmental and host genetic components. In terms of host components, segregation analysis and twin studies strongly support the role of host genetic components in determining the chronicity of HBV infection. 4, 5 In addition, several studies revealed that variants of several host genes, including human leukocyte antigen, cytokines and chemokines were associated with persistent HBV infection or HBV clearance. [6] [7] [8] [9] [10] Recently, a genome-wide association study demonstrated that genetic variation in HLA-DP locus was strongly associated with chronic hepatitis B in Japanese and Thai populations, 11 which was further confirmed in Chinese Han population 12 . Furthermore, our previous genome-wide association study identified novel susceptibility loci on 6p21.32 and 21q21.3 for HCC in chronic HBV carriers. 13 Interleukin 6 (IL-6), through interaction with its receptor (IL-6R), is expressed by a variety of cell lineages and has diverse functions. Being a key pro-inflammatory cytokine, increased IL-6 level has been reported to be associated with hepatic inflammation and with progression of chronic viral hepatitis caused by HBV, hepatitis C virus (HCV) infection to HCC. 14 IL-6 also serves as a key regulator in modifying the profile of adaptive cellular immune response, 15 which is critical to the outcome of pathogen infection, by activating of IL-6R on immune cells. Consistently, genetic variants of IL-6 have been linked to the susceptibility to a wide range of infectious diseases, including chronic HCV infection, persistent Chlamydia pneumoniae infection, respiratory tract infection and tuberculosis. [16] [17] [18] [19] IL6 promoter functional polymorphism rs1800796 affects spontaneous clearance of HBV infection. 20 In addition, male subjects with the GG and CG genotypes have higher susceptibility to HBV-related HCC than those with CC genotype. 21 However, the mechanism of rs1800796 in regulating HBV infection and progress remains obscure. In the present study, we investigated the association between IL6 gene rs1800796 polymorphism and the outcome of CHB infection in Chinese population. Our study revealed a novel mechanism of rs1800796 polymorphism in the outcome of HBV infection, that is, the polymorphism influences T-helper 17 (Th17)/regulatory T cell (Treg) balance through modulation C/EBPα-binding activity and IL-6 production.
RESULTS

Association between rs1800796 polymorphism and susceptibility to HBV, HCV and HIV infection in experimental cohort
To analyze the relationship between rs1800796 and the susceptibility to viruses infection, we determined rs1800796 genotypes by TaqMan assays among cohorts of HBV, HCV, HIV patients and healthy controls. The alleles and genotypes distribution of rs1800796 in various cohorts were shown in Table 1 , and all markers were in Hardy-Weinberg equilibrium. The rs1800796 single-nucleotide polymorphism (SNP) was associated with susceptibility to HBV infection (P = 0.0003, odds ratio (OR) = 1.43), but not to HCV and HIV infection. The distribution of rs1800796 genotypes (CC, CG and GG) also varies significantly between HBV group and healthy controls. A gene dose effect for the susceptibility allele C was observed when the CC and CG genotypes were separately compared with GG genotype with ORs of 1.78 and 1.19, respectively. A recessive model showed that the genotype frequency of CC was much higher in the HBV group compared with (GG+CG) genotype (P = 0.0004, OR = 1.53). All the above indicate that the 'C' allele is associated with increased risk of HBV infection.
Replication of association between rs1800796 polymorphism and susceptibility to HBV infection in validation cohort
The association between rs1800796 polymorphism and susceptibility to HBV infection was further validated in the validation cohort, which involved 282 cases and 276 controls. Individuals with C allele showed increased HBV susceptibility with OR of 1.42 (95% confidence intervals = 1.06-1.89, P = 0.017; Table 2 ). Analysis on pooled data (848 cases and 894 controls) showed even more significant association with an OR of 1.43 (95% confidence intervals = 1.21-1.68, P o0.0001; Table 2 ). Together, the genetic studies from the experimental cohort and the validation cohort were consistent and these results showed rs1800796C allele was associated with increased HBV susceptibility in Chinese population.
The rs1800796 polymorphism is related to serum ALT level, but not to HBV viral load in CHB patients Serum alanine aminotransferase (ALT) level is a sensitive marker for hepatic inflammation and liver injury, which reflects the interaction between host and HBV. Increased serum ALT and HBV DNA level have been recognized as important risk predictors for HCC and liver cirrhosis in patients with CHB infection. 3 Therefore, we analyzed the relationship between serum ALT or HBV DNA level and rs1800796 polymorphism. As expected, ALT levels were significantly higher in CHB patients with CC or CG genotype than those with GG genotype (Figure 1a ). A similar trend was observed for serum aspartate transaminase level (Figure 1b ), although the difference was not significant. In contrast, no difference in HBV DNA load was found among CHB patients carrying different rs1800796 genotypes ( Figure 1c ).
Functional assay of rs1800796 polymorphism on IL6 transcriptional activity and IL-6 production SNPs in the IL6 promoter region have been reported to influence IL-6 expression. However, the influence of a given SNP is cell-type specific and could be affected by the neighbor SNPs. 22 To investigate the effect of rs1800796 on promoter activity of the IL6 gene, a 1081-bp promoter region of the IL6 gene carrying rs1800796C allele was cloned into pGL3 construct (pGL3/-572C). To specifically assess the influence of C or G allele on IL-6 promoter activity, the pGL3/-572C vector was mutated to pGL3/-572G. Compared with pGL3/-572G, the pGL3/-572C conferred over twofold higher transcription activities as determined by reporter luciferase activity in transfected HeLa cells (Figure 2a ), suggesting the direct effect of rs1800796 polymorphism, but not other SNPs in linkage disequilibrium with this polymorphism, on transcription activity of IL-6 promoter.
To investigate the influence of rs1800796 on IL-6 production, we measured the plasma IL-6 level in healthy controls and patients with chronic hepatitis B. Consistent with the result of promoter activity assay, individuals with rs1800796 GG genotype have lower plasma IL-6 levels compared with those with rs1800796 CC genotype, irrespective of HBV infection status, albeit it is not statistically significant ( Figure 2b ).
Among immune cells, macrophages or monocytes are the main cell source of IL-6 production. We therefore evaluated the effect of rs1800796 polymorphism on IL-6 production by CD14 + monocytes purified from the peripheral blood. In the absence of stimulation, monocytes isolated from healthy controls carrying rs1800796 CC genotype spontaneously produce higher level of IL-6 than those with GG genotype, although the difference is not significant. On stimulation with HBV core antigen, monocytes from individuals with rs1800796 CC genotype produce significantly more IL-6 than those carrying GG genotype ( Figure 2c ). Therefore, our data indicated that rs1800796 in the promoter region of IL6 gene have a direct role in regulation of IL-6 production in monocytes.
Influence of rs1800796 polymorphism on the balance of Th17 and Treg cells in CHB patients IL-6 has been reported to have a critical role in regulating the balance of Th17 and Treg cells, which is important to determine the severity of hepatic inflammation of CHB infection. [23] [24] [25] [26] [27] As we found that rs1800796 polymorphism of IL6 promoter influences IL-6 production, we further investigated whether rs1800796 polymorphism influences the balance between Th17 and Treg cells in 56 CHB patients. Figure 3 shows that patients with rs1800796 GG genotype have significantly lower Th17/Treg ratio compared with those with CC or CG genotypes ( Figure 3 ). This effect of rs1800796 polymorphisms on Th17/Treg ratio is correlated with serum ALT levels in CHB patients ( Figure 1a ). Thus, in line with previous reports that the balance between Th17/Treg affects the severity of liver damage in CHB patients, [23] [24] [25] [26] our data suggest that influence of rs1800796 on Th17/Treg balance might be the important mechanism underlying the susceptibility to HBV infection. The rs1800796 polymorphism influences the transcription factor C/EBPα-binding activity to IL6 promoter To investigate nuclear protein binding activity of variants in rs1800796, we used electrophoretic mobility-shift analysis to assess the biological consequences of rs1800796 polymorphism in vitro. Synthetic allele-specific oligonucleotides corresponding to the polymorphic rs1800796 site were incubated with nuclear protein extracts from HeLa cell. One strong band (complex 1) was shifted when the nuclear extracts were incubated with biotinlabeled rs1800796 C probe (Figure 4a , lane2). In contrast, there was much less complex 1 formation on the rs1800796 G probe (Figure 4a , lane 6). Furthermore, complex 1 formation was specifically blocked by unlabeled rs1800796 C or rs1800796 G competitor ( Figure 4a , lanes 3, 4, 7 and 8). These results indicated that rs1800796 C variant increased the binding activity of one or more nuclear protein to an IL6 promoter region, to form the transcription initiation complex. To determine the identity of this nuclear protein, we therefore conducted supershift experiments and antibodies against a variety of IL-6-inducible transcription factors SP1, ZEB1, MEF2, C/EBPa, C/EBPβ, PU.1 and TBP were used. Some supershifting were seen with C/EBPa antibody and reduced intensity of the complex 1 significantly (Figure 4b , lanes 5 and 9). These results verify the interaction of transcription factor C/EBPa with the IL6 gene and rs1800796 polymorphisms influence the C/EBPa-binding activity.
DISCUSSION
In this study, we compared the rs1800796 genotype distribution in IL6 promoter region in patients with CHB, HCV and HIV infection and healthy controls. The results revealed that the SNP rs1800796 is associated with susceptibility to CHB infection, but not to HCV and HIV infection. SNP rs1800796 polymorphism regulates IL-6 transcription activity and IL-6 production in CD14 + monocytes. Furthermore, the susceptibility rs1800796C allele is linked to increased Th17 cells response and ratio of Th17/Treg in untreated CHB patients, suggesting that the susceptibility conferred by IL6 gene polymorphism may through its effect on the balance of Th17/Treg. Finally, the rs1800796C allele shows higher binding activity with C/EBPa, which reveals the new mechanism leading to downstream Th17/Treg imbalance. Polymorphisms in the promoter region of the IL6 gene including -597G4A (rs1800797) and -174G4C (rs1800795) have been reported in association with the outcome of HCV infection. 17, 28, 29 In contrast, various previous studies reported a lack of association between IL6 promoter polymorphisms (in particular 1 800 795) and the outcome of CHB infection. [30] [31] [32] [33] Most of these studies selected only rs1800795 to analyze. However, as the frequency of the minor C allele of rs1800795 was found to be very low, it is not possible to identify any significant association. 34, 35 A recent study performed in Italy indicated that rs1800795 polymorphism with variants over 5% affects chronic hepatitis B. 36 In our study, we showed rs1800796 with minor allele G frequencies of 0.25 was associated with reduced HBV susceptibility in a pooled cohort. Recently, G allele of rs1800796 was found to be associated to spontaneous clearance of HBV infection. 20 Furthermore, Tang et al. 21 reported that male subjects with the GG and CG genotypes have higher susceptibility to HBV-related HCC than those with CC genotype; however, according to our study the rs1800796G allele reduced IL-6 production and IL-6 could inhibit the proliferation of HCC cells by regulating cdk2/cdk4, p21 (waf1/cip1) and p27 (Kip1) expression through the signal transducer and activator of transcription 3 pathway. 37 Taken together, the rs1800796 G allele could be considered as a protective marker of HBV infection, but a risk marker of HCC. Although the specific susceptibility SNP to HBV infection identified in our study is different from that reported by Fabris et al., 36 both studies indicated that possessing of an IL-6 high-producer genotype (that is, rs1800796 CC or rs1800795 GG) may have disadvantages during CHB infection. 36 The C allele frequency of rs1800796 is significantly higher in Chinese Han population than Western populations (Han Chinese in Beijing, 0.767; Utah residents with ancestry from northern and western Europe, 0.043). The prevalence of CHB, HCV and HIV infection among Chinese populations and Caucasian populations is in contrast to the ethnic difference. 3, [38] [39] [40] Therefore, the ethnic difference of IL-6 gene polymorphisms might, at least partially, be the cause of the different spectrum of HBV, HCV and HIV infection prevalence. At the same time, it also serves as another evidence to validate our finding that rs1800796 polymorphism is associated with susceptibility to HBV infection.
More importantly, the susceptibility allele rs1800796 C is associated with elevated ALT levels in patients with HBV infection. Increased IL-6 level has been reported to associated with hepatic inflammation caused by HBV and HCV infection. 14 In addition, it was reported that HIV-1 gp120 also induces expression of IL-6 through nuclear factor-κB or phosphatidyl inositol 3-kinase/Akt pathway. 41 In consistent, higher plasma IL-6 level was found in carriers with C allele than those without C allele in both controls and cases, although the differences are not statistically different. Functional assay revealed that C allele of rs1800796 confers significantly higher IL-6 gene transcription. In addition, CD14 + monocytes isolated from C allele carriers produced significantly more IL-6 in response to HBV core antigen stimulation. Therefore, similar to what was observed in HCV infection and rs1800795 polymorphism, rs1800796 polymorphism affects the expression of IL-6. C allele carriers with higher IL-6 production genotype are associated with susceptibility to CHB infection and severer hepatic inflammation. Serum ALT level reflects interaction between host and virus, and has been recognized as a risk predictor to cirrhosis and HCC in patients with CHB. 42 Thus, IL6 gene polymorphism may be associated with disease progress to cirrhosis and HCC in CHB infection, and further study is warranted to clarify this hypothesis.
By interaction with IL-6R on CD4 T cells, IL-6 has an important role in regulating the profile of CD4 T-cell response, which is critical to the outcome of HBV infection. In particular, increasing number of reports demonstrated that Th17 cells and its effector cytokine IL-17 have a major role in HBV-associated liver inflammation and hepatocellular damages. 43, 44 To control the excessive detrimental effect of Th17 cells, suppressive Treg is also induced during HBV infection, and therefore the balance of Th17/Treg more accurately reflect the clinical outcome of HBV infection than Th17 or Treg alone. [23] [24] [25] [26] [27] Given that IL-6 is the key cytokine in determining the balance of Th17/Treg, it is not surprising to find that the functional SNP rs1800796 affects the balance of Th17/Treg response, which may in turn determine hepatic inflammation during HBV infection. On the other hand, there is no difference of HBV viral load among CHB patients with different rs1800796 genotypes, which is consistent with recent reports showing no association between Th17 frequency and HBV viral load in patients with HBV infection. 23, 44, 45 We found that rs1800796 polymorphism formed complexes with nuclear extracts, indicating that lots of transcription factors bound to the region of rs1800796. In supershift experiment, we found the main band of these complexes binding to rs1800796 Figure 2 . Influence of SNP rs1800796 on IL6 gene transcription activity and IL-6 production. (a) Influence of variants at -572C4G (rs1800796) on IL6 promoter activity. Luciferase activity in HeLa cells transfected with pGL3-Basic vector (vector), pGL3-572C plasmid (-572C), pGL3-572G plasmid (-572G) and positive control plasmid (positive control) were showed. There was more than twofold increase in the transcription activity of the promoter carrying C allele at -572 in comparison with that carrying G allele. (b) Plasma IL-6 levels in controls and chronic hepatitis B cases with different rs1800796 genotype. A total of 15 controls had genotype CC, 15 controls had genotype CG and 15 controls had genotype GG. A total of 20 cases had genotype CC, 15 had genotype CG and 4 had genotype GG. (c) IL-6 production by purified CD14 + monocytes with different rs1800796 genotypes. Monocytes (CD3 − CD19 − CD14 + ) were isolated from peripheral blood mononuclear cells of healthy controls with different rs1800796 genotypes. Monocytes (2 × 10 6ml − 1 ) were left unstimulated or were cultured with HBV core antigen (HBcAg; 10 μg ml − 1 ) for 48 h. The concentration of secreted IL-6 was determined by enzyme-linked immunosorbent assay. Six specimens had genotype CC, six had genotype CG and five had genotype GG. *P o 0.05 and ***P o0.001.
was C/EBPα. In addition, C/EBPα had different affinity to C or G allele of rs1800796, in which C allele binds higher to C/EBPα than G allele does. C/EBPα contains 358 amino acid residues and C-terminal basic region-leucine zipper (BR-LZ or bZIP) DNAbinding domain. C/EBPα, which bind the DNA motif 5'-T(T/G) NNGNAA(T/G)-3′, activates transcription via its two N-terminal transactivation domains. Meanwhile, C/EBPα as obligatory homodimers bind the DNA and heterodimerize with members of C/EBP, CREB or AP-1 families as well. In C/EBPα − / − mice, IL-6 receptor and gp130 were markedly downregulated. 46 Moreover, C/EBPα can act as a transcription factor to regulate a large amount of acute phase protein, which involve in infection, inflammatory and tissue injury. Similarly, our results show that C/EBPα-binding activity could affect HBV progress through regulating IL-6 expression, which in turn modulate Th17/Treg balance.
In summary, our study revealed that the functional polymorphism (rs1800796) in the promoter region of the IL6 gene is associated with the outcome of HBV infection. The increased risk of hepatic inflammation with rs1800796C allele might be due to its effect on alteration of the Th17/Treg balance and regulation with C/EBPα-binding activity. Our findings suggested that appropriate manipulation of IL-6 signal might be useful for prevention and treatment of HBV infection.
MATERIALS AND METHODS
Participants recruitment, study design and samples collection
To investigate the association between IL6 gene polymorphisms and the outcome of HBV infection, we set up two HBV cohorts and enrolled participants of Chinese Han population, who visited clinic for annual regular physical examination at Shenzhen Third People's Hospital. The subjects enrolled from December 2008 to December 2010 were used as our experimental cohort (566 cases with HBV infection and 618 healthy controls) and subjects enrolled from June 2014 to June 2015 were considered as our validation cohort (282 cases with HBV infection and 276 healthy controls). Meanwhile, the HCV and HIV cohort were considered as disease control in experimental cohort. Disease diagnostic criteria were referred to the guidelines of prevention and treatment for infectious diseases published by the ministry of health of China. [47] [48] [49] The healthy control group was formed by subjects who had no history of HBV, HCV, HIV infection or other conspicuous diseases. A total 848 patients who were serum positive for the HBV surface antigen and with no history of anti-viral treatment formed the HBV group. Furthermore, following the criteria described previously 44, 50 , all HBV cases with elevated ALT levels (ALT 440 U l − 1 ) were diagnosed as CHB. The HCV and HIV cases were formed by HCV-RNA-positive and HIV-RNA-positive adult patients, respectively. Characteristics of all the study population are shown in Table 3 . This study was reviewed and approved by Shenzhen Third People's Hospital Ethics Committee. Written informed consent was obtained from all study participants before collection of blood samples.
DNA extraction and SNP genotyping
Genomic DNA was extracted from blood samples, using the QIAamp DNA Blood Mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. DNA purities and final concentrations were determined spectrophotometrically. The SNP rs1800796 was genotyped with TaqMan assays in 50 μl reaction volume, using ABI 7500 real-time PCR systems (ABI, Carlsbad, CA, USA).
Plasmid construction
A 1081-bp sequence of the IL6 promoter region, from − 1029 to +52 obtained from a subject with CC genotype at position − 572 was cloned into the pGL3-Basic vector (Promega, Madison, WI, USA). The primers used to PCR genomic DNA, were 5′-CATCTCGAGTCAGAGCCTAG AGCCGTGCC TGC-3′ (forward, underlined letters showed XhoI site) and 5′-CATAAGCTT AGCCTCAGACATCTCCAGTCCT-3′ (reverse, underlined letters showed HindIII site). The resulting XhoI-digested and HindIII-digested PCR fragment was directly cloned into the XhoI-HindIII sites of pGL3-Basic vector (pGL3/-572C). The pGL3/-572C vector was mutated to pGL3/-572G, using QuickChang II Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) using the primers 5′-GTTCTACAACAGCCGCTCACA GGG AGAGC-3′ (forward) and 5′-GCTCTCCCTGTGAGCGGCTGTTGTAGAAC-3′ (reverse), in which the underlined letter showed the altered nucleotide.
Transient transfection and reporter assays
The human-derived epithelial-like cell line HeLa was cultured in Roswell Park Memorial Institute 1640 medium (Hyclone, Logan, UT, USA), supplemented with 10% fetal calf serum (Hyclone), 2 mM L-glutamine, 100 U l − 1 penicillin-streptomycin for each, 23 mM sodium bicarbonate, at 37°C in a humidified atmosphere containing 5% CO 2 . Transient transfections were performed using Lipofectamine 2000 reagent (Life Technologies, Carlsbad, CA, USA). Briefly, 2 × 10 5 HeLa cells were seeded into 24-well plates and incubated for 12 h, the cultured cells were co-transfected with 0.7 μg of constructed vectors or pGL3-Basic original vector, or positive control vector under SV40 promoter, and 0.1 μg of internal control Renilla luciferase reporter plasmid pRL-CMV. After additional 24 h incubation, the plates were washed with phosphate-buffered saline; luciferase activity of transfected cells was measured using Dual-Glo luciferase assay system (Promega). Firefly luciferase was normalized against Renilla luciferase activity, to account for variation in transfection assay. All experiments were performed at least twice, with each transfection in triplicate. CD14 + monocytes isolation and cell culture CD14 + monocytes was purified from peripheral blood mononuclear cells by using flow cytometry as described previously. 18 Purified CD14 + monocytes were cultured in the absence or presence of 10 μg ml − 1 HBV core antigen. The supernatants of cell culture were collected 72 h later for IL-6 measurement.
Intracellular staining and flow cytometry analysis
The frequencies of Th17 cells were measured by flow cytometry as described previously. 44, 51 For Treg cell staining, fresh heparinized peripheral blood (100 μl) was stained with antibodies against CD3, CD4, CD25 and CD127 (BD Biosciences, San Jose, CA, USA). Treg was defined as CD3 + CD4 + CD25 + CD127 − . 52 At least 0.2 million cells were acquired and analysis using FACSDiva software (BD Biosciences).
Detection of IL-6 by enzyme-linked immunosorbent assay
The concentrations of IL-6 in supernatants and plasma were measured by enzyme-linked immunosorbent assay, following the manufacturer's instruction (R&D, Minneapolis, MN, USA).
Electrophoretic mobility-shift assay
Nuclear extracts were prepared from Hela as reported previously. 53 The sense probe sequences were as follows: rs1800796 C probe, 5′-CCAGGCAG TTCTACAACAGCCCCTCACAGGGAGAGCCAGAACA-3′ and rs1800796 G probe, 5′-CCAGGCAGTTCTACAACAGCCGCTCACAGGGAGAGCCAGAACA-3′. DNA probes were prepared with the Biotin 3′-End DNA Labeling Kit (Pierce, Rockford, IL, USA). Electrophoretic mobility-shift assays were performed by using the LightShift chemiluminescent electrophoretic mobility-shift analysis kit (Pierce). Binding reactions were performed as follows: 1 × binding buffer (10 mM Tris, 50 mM KCl, 3 mM MgCl 2 , 0.1 mM EDTA and 1.0 mM dithiothreitol), 20 fmol biotin-labeled double-stranded probe, 2.0 μl nuclear extract and 1.0 μg poly(dI : dC) were incubated at room temperature for 20 min in a total volume of 20 μl. For competition studies, nuclear extracts were incubated with a 200-fold unlabeled oligonucleotide for 20 min before the addition of labeled probe. In antibody supershift assays, 1 μg of anti-ZEB1, anti-MEF2, anti-C/EBPα, anti-C/EBPβ, anti-PU.1, anti-TBP and anti-SP1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were added after binding of nuclear extracts to labeled probe and incubated for 20 min at room temperature.
Statistical analysis
The allele and genotype frequencies were determined by direct counting. The Pearson's χ 2 -test was used to compare allele and genotype distribution IL6 gene allele-specific C/EBPα binding activity G Zhang et al in cases and controls. ORs and 95% confidence intervals were calculated with Miettinen's method. The Hardy-Weinberg equilibrium of SNP was determined by the HWE program. One-way analysis of variance with Bonferroni correction was used to compare IL-6 levels, ALT level and the frequencies of Th17 cells and Treg, among participants with different genotypes. All computations were done using GraphPad Prism software (version 4.0) (GraphPad Software, La Jolla, CA, USA). A P-value of o 0.05 was considered significant.
